RecruitingPhase 2NCT06823427

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Studying Upper tract urothelial carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Intervention
9MW2821(drug)
Enrollment
60 target
Eligibility
18-80 years · All sexes
Timeline
20252027

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06823427 on ClinicalTrials.gov

Other trials for Upper tract urothelial carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Upper tract urothelial carcinoma

← Back to all trials